Literature DB >> 25701466

ACE I/D genotype-related increase in ACE plasma activity is a better predictor for schizophrenia diagnosis than the genotype alone.

Ary Gadelha1, Camila M Yonamine2, Vanessa K Ota3, Vitor Oliveira4, João Ricardo Sato5, Sintia I Belangero6, Rodrigo A Bressan1, Mirian A F Hayashi7.   

Abstract

BACKGROUND: Angiotensin-I converting enzyme (ACE) is a key component of the renin-angiotensin system (RAS). Although the several contradictory data, ACE has been associated with schizophrenia (SCZ) pathophysiology. Here the ACE activity of SCZ patients and healthy controls (HCs), and its possible correlations with the ACE polymorphism genotype and symptomatic dimensions, was investigated.
METHODOLOGY: ACE activity of 86 SCZ patients and 100 HCs paired by age, gender and educational level was measured, using the FRET peptide substrate and the specific inhibitor lisinopril. The ACE insertion/deletion (I/D) genotypes were assessed by the restriction fragment length polymorphism (RFLP) technique.
RESULTS: Significantly higher ACE activity was observed in SCZ patients compared to HCs (t=-5.09; p<0.001). The area under the receiver operating characteristic (ROC) curve was 0.701. Mean ACE activity levels were higher for the D-allele carriers (F=5.570; p=0.005), but no significant difference was found among SCZ patients and HCs for genotypes frequencies (Chi-squared=2.08; df=2; p=0.35). Interestingly, we found that the difference between the measured ACE activity for each SCZ patient and the expected average mean value for each respective genotype group (for control subjects) was a better predictor of SCZ than the ACE dichotomized values (high/low) or ACE I/D.
CONCLUSION: Our results suggest that higher levels of ACE activity are associated with SCZ with stronger impact when the genetic background of each individual is considered. This may explain the heterogeneity of the results on ACE previously reported.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACE; Enzyme activity; Genotype; Oligopeptidase; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25701466     DOI: 10.1016/j.schres.2015.01.044

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.

Authors:  Kristen M Ward; A Zarina Kraal; Stephanie A Flowers; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2017-08-02       Impact factor: 4.705

2.  The insertion/deletion polymorphism in the angiotensin-converting enzyme gene and nicotine dependence in schizophrenia patients.

Authors:  Sergej Nadalin; Smiljana Ristić; Jelena Rebić; Vesna Šendula Jengić; Miljenko Kapović; Alena Buretić-Tomljanović
Journal:  J Neural Transm (Vienna)       Date:  2016-12-27       Impact factor: 3.575

3.  The genetic polymorphisms of angiotensin converting enzyme insertion/deletion and glioma susceptibility: A meta-analysis.

Authors:  Meili Sun; Yuying Fang; Shuzhen Ma; Ximei Gao; Yuping Sun
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

4.  Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia.

Authors:  Banny Silva Barbosa Correia; João Victor Nani; Raniery Waladares Ricardo; Danijela Stanisic; Tássia Brena Barroso Carneiro Costa; Mirian A F Hayashi; Ljubica Tasic
Journal:  Biomedicines       Date:  2021-02-26

5.  Diagnostic Performance of Increased Malondialdehyde Level and Oxidative Stress in Patients with Schizophrenia.

Authors:  Onur Hurşitoğlu; Fatma Özlem Orhan; Ergül Belge Kurutaş; Adem Doğaner; Hüseyin Toygun Durmuş; Hatice Kopar
Journal:  Noro Psikiyatr Ars       Date:  2021-05-17       Impact factor: 1.339

6.  Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia.

Authors:  A Gadelha; A M Vendramini; C M Yonamine; M Nering; A Berberian; M A Suiama; V Oliveira; M T Lima-Landman; G Breen; R A Bressan; V Abílio; M A F Hayashi
Journal:  Transl Psychiatry       Date:  2015-12-08       Impact factor: 6.222

7.  A study in first-episode psychosis patients: does angiotensin I-converting enzyme (ACE) activity associated with genotype predict symptoms severity reductions after treatment with the atypical antipsychotic risperidone?

Authors:  João V Nani; Caroline Dal Mas; Camila M Yonamine; Vanessa K Ota; Cristiano Noto; Sintia I Belangero; Jair J Mari; Rodrigo Bressan; Quirino Cordeiro; Ary Gadelha; Mirian A F Hayashi
Journal:  Int J Neuropsychopharmacol       Date:  2020-07-22       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.